Transaction DateRecipientSharesTypePriceValue
4th January 2021Jeffrey Alan Wolf288,100Grant/award etc.$0.00
4th January 2021John K A Prendergast138,272Grant/award etc.$0.00
12th November 2020Edward B Iii Smith103,304Open or private sale$1.03$106,403.12
13th August 2020William L. Ostrander4,440Payment by withholding$1.83$8,125.20
13th August 2020William L. Ostrander15,625Exercise of derivative$0.52$8,125.00
16th June 2020John K A Prendergast99,000Grant/award etc.$0.00
2nd January 2020Jeffrey Alan Wolf1,980,000Grant/award etc.$0.00
2nd January 2020John K A Prendergast400,000Grant/award etc.$0.00
31st December 2019Jeffrey Alan Wolf900,000Grant/award etc.$0.00
24th June 2019John K A Prendergast84,000Grant/award etc.$0.00
Heat Biologics
Heat Biologics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Heat Biologics, Inc. is a clinical stage company. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot. Its product candidates are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.

Ticker: HTBX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1476963
Employees: 36
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags